Business Description
Relief Therapeutics Holding SA
ISIN : US7595JP3044
Share Class Description:
RLFTY: ADRCompare
Compare
Traded in other countries / regions
RLF.SwitzerlandRLFTY.USA0QKQ.UKV6M.Germany IPO Date
2021-11-15Description
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.44 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -6.66 | |||||
| Beneish M-Score | -1.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -108 | |||||
| 3-Year EPS without NRI Growth Rate | 22.1 | |||||
| 3-Year FCF Growth Rate | 20.2 | |||||
| 3-Year Book Growth Rate | -20.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.67 | |||||
| 9-Day RSI | 56.91 | |||||
| 14-Day RSI | 60.68 | |||||
| 6-1 Month Momentum % | 133.33 | |||||
| 12-1 Month Momentum % | 34.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | |||||
| Quick Ratio | 3.01 | |||||
| Cash Ratio | 2.25 | |||||
| Days Inventory | 66.7 | |||||
| Days Sales Outstanding | 44.57 | |||||
| Days Payable | 216.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.6 | |||||
| Shareholder Yield % | 0.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.68 | |||||
| Operating Margin % | -142.86 | |||||
| Net Margin % | -538.23 | |||||
| FCF Margin % | -123.29 | |||||
| ROE % | -70.82 | |||||
| ROA % | -50.8 | |||||
| ROIC % | -14.5 | |||||
| 3-Year ROIIC % | 32.56 | |||||
| ROC (Joel Greenblatt) % | -1728.91 | |||||
| ROCE % | -60.42 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 14.88 | |||||
| PS Ratio | 9.14 | |||||
| PB Ratio | 1.6 | |||||
| EV-to-EBIT | -1.3 | |||||
| EV-to-EBITDA | -1.39 | |||||
| EV-to-Forward-EBITDA | -1.09 | |||||
| EV-to-Revenue | 7.92 | |||||
| EV-to-Forward-Revenue | 0.43 | |||||
| EV-to-FCF | -6.49 | |||||
| Earnings Yield (Greenblatt) % | -76.92 | |||||
| FCF Yield % | -13.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:RLFTY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Relief Therapeutics Holding SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 9.725 | ||
| EPS (TTM) ($) | -4.171 | ||
| Beta | 0.99 | ||
| Volatility % | 176.91 | ||
| 14-Day RSI | 60.68 | ||
| 14-Day ATR ($) | 0.557018 | ||
| 20-Day SMA ($) | 6.705025 | ||
| 12-1 Month Momentum % | 34.87 | ||
| 52-Week Range ($) | 1.05 - 7.56 | ||
| Shares Outstanding (Mil) | 12.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Relief Therapeutics Holding SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Relief Therapeutics Holding SA Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Relief Therapeutics Holding SA Frequently Asked Questions
What is Relief Therapeutics Holding SA(RLFTY)'s stock price today?
The current price of RLFTY is $7.03. The 52 week high of RLFTY is $7.56 and 52 week low is $1.05.
When is next earnings date of Relief Therapeutics Holding SA(RLFTY)?
The next earnings date of Relief Therapeutics Holding SA(RLFTY) is 2025-02-14 Est..
Does Relief Therapeutics Holding SA(RLFTY) pay dividends? If so, how much?
Relief Therapeutics Holding SA(RLFTY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers